Search for Clinical Trial Results

Sponsored By

Blastic Plasmacytoid Dendritic Cell - 7 Studies Found

Status Study
Completed Study Name: SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia
Condition:
  • Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
  • Acute Myel
    Date: 2014-03-13
    Interventions: Drug: SL-401
Completed Study Name: Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
Condition:
  • Adult Acute Myeloid Leukemia in Remission
  • Donor
  • Early Rela
    Date: 2014-06-06
    Interventions:
    • Drug: cyclophosphamide Given I
Completed Study Name: Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN)
Condition:
  • Blastic Plasmacytoid Dendritic Cell Neoplasm
  • Hematological Mali
    Date: 2016-07-21
Active, not recruiting Study Name: DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
Condition:
  • Leukemia
  • Myelodysplastic Syndromes
  • B
    Date: 2006-11-08
    Interventions: Drug: DT388IL3 Intravenously via a 3 cc plastic syringe as a 15 minute bolus infusion daily for five day
Recruiting Study Name: PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies
Condition:
  • Acute Myelogenous Leukemia
  • B-cell Acute Lymphoblastic Leukemia
  • Adult Nasal Type Extranodal NK/T-Cell Lymphoma
  • Adult T-Cell Leukemia/Lymphoma
  • Date: 2016-01-08
    Interventions:
    • Other: Laboratory Biomarker Analysis

Active, not recruiting Study Name: An Open-label Phase II Study of Lorvotuzumab Mertansine
Condition: Leukemia
Date: 2015-04-15
Interventions: Drug: Lorvotuzumab Mertansine (IMGN901) 100 mg/m2 by vein on Day 1 and 8 of a 21-day cycle.